AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10660242 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl 3 microg/kg
Number of subjects: 18
Study 10660242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 3 microg/kg
Number of subjects: 18
Study 10660242 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (control)
Number of subjects: 18
Study 7715908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous IL-2 (3 million IU/day for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally)
Number of subjects: 50
Study 7715908 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 50
Study 2476765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate responsive pacing (VVIR)
Number of subjects: 17
Study 339662 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily during three consecutive days, every fortnight)
Number of subjects: 24
Study 339662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31496316 — intervention group
Group type: EXPERIMENTAL
Intervention: Periulcer foam sclerotherapy injection using Aethoxysklerol 1%
Number of subjects: 20
Study 31496316 — intervention group
Group type: EXPERIMENTAL
Intervention: Periulcer foam sclerotherapy injection
Number of subjects: 20
Study 31138732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory PEP
Number of subjects: 0
Study 31138732 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Compression
Number of subjects: 0
Study 31138732 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 27557825 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Approach (PA) intervention with implementation strategy including working group meeting, supervisor training, and optional coaching.
Number of subjects: 273
Study 27557825 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving written information about the PA only.
Number of subjects: 273
Study 25994074 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion (2 pmol kg(‐1) min(‐1))
Number of subjects: 17
Study 25994074 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion with hyperinsulinaemic-euglycaemic (EU) clamp
Number of subjects: 17
Study 25994074 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion with hyperinsulinaemic-hyperglycaemic (HC) clamp
Number of subjects: 17
Study 25994074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole GIP infusion
Number of subjects: 17
Study 25994074 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (154 mmol/l NaCl)
Number of subjects: 17
Study 25994074 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion with hyperinsulinaemic-euglycaemic (EU) clamp
Number of subjects: 17
Study 25994074 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion with hyperinsulinaemic-hyperglycaemic (HC) clamp
Number of subjects: 17
Study 25994074 — intervention group
Group type: COMPARATOR
Intervention: Sole placebo infusion
Number of subjects: 17
Study 23230099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial intervention
Number of subjects: 150
Study 23230099 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 150
Study 21740192 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT-ECG
Number of subjects: 824
Study 21740192 — intervention group
Group type: COMPARATOR
Intervention: ETT-MPS
Number of subjects: 824
Study 18979143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (150 mg bd)
Number of subjects: 20
Study 16280461 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental prosopagnosic subject (SO)
Number of subjects: 10
Study 16280461 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 10
Study 12735087 — intervention group
Group type: EXPERIMENTAL
Intervention: Zestra for Women (botanical feminine massage oil)
Number of subjects: 20
Study 12735087 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 20
Study 10859095 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 27
Study 10859095 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment
Number of subjects: 27
Study 10859095 — intervention group
Group type: COMPARATOR
Intervention: Minimal or no treatment
Number of subjects: 27
Study 9294990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin + Gemfibrozil (20 mg + 1200 mg/day)
Number of subjects: 389
Study 9294990 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Gemfibrozil (20 mg + 1200 mg/day)
Number of subjects: 389
Study 9294990 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Ciprofibrate (20 mg + 100 mg/day)
Number of subjects: 389
Study 9294990 — intervention group
Group type: EXPERIMENTAL
Intervention: All combination treatments
Number of subjects: 389
Study 9294990 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Gemfibrozil
Number of subjects: 389
Study 8485447 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 300 micrograms p.o.
Number of subjects: 50
Study 8485447 — intervention group
Group type: COMPARATOR
Intervention: Dipotassium clorazepate, 0.3 mg.kg‐1 p.o.
Number of subjects: 50
Study 2894282 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 31449805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 152
Study 31449805 — intervention group
Group type: COMPARATOR
Intervention: Medications
Number of subjects: 152
Study 29218767 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful directives
Number of subjects: 197
Study 29218767 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful directives
Number of subjects: 197
Study 29218767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency and connectedness (FC)
Number of subjects: 197
Study 29218767 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction quality
Number of subjects: 197
Study 26669912 — intervention group
Group type: EXPERIMENTAL
Intervention: GOL 100 mg + placebo (Group 2)
Number of subjects: 444
Study 26669912 — intervention group
Group type: EXPERIMENTAL
Intervention: GOL 50 mg + MTX (Group 3)
Number of subjects: 444
Study 26669912 — intervention group
Group type: EXPERIMENTAL
Intervention: GOL 100 mg + MTX (Group 4)
Number of subjects: 444
Study 26669912 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 444
Study 26669912 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX (Group 1)
Number of subjects: 444
Study 24196556 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 100
Study 24196556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 100
Study 22634077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinicians received educational toolbox, seminars, teleconferences, mini-fellowships, opinion leader visits, clinician-specific feedback, and pay for performance.
Number of subjects: 88
Study 22634077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinicians participated in 17 interventions over 36 months.
Number of subjects: 88
Study 22634077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-efficacy scores at baseline.
Number of subjects: 88
Study 20399985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (20 and 30 mg)
Number of subjects: 58
Study 20399985 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (7.5 and 10 mg)
Number of subjects: 58
Study 18719448 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day ambulatory continuous lumbar plexus block with 0.2% ropivacaine
Number of subjects: 47
Study 18719448 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 47
Study 15884026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse coaching
Number of subjects: 111
Study 15884026 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 111
Study 12882611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis of ketoprofen gel using continuous ultrasound (1 MHz, 1.5 W/cm2, for 5 minutes)
Number of subjects: 26
Study 12882611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis of ketoprofen gel using pulsed ultrasound (100 Hz, 20% duty cycle)
Number of subjects: 26
Study 12882611 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound with ketoprofen gel
Number of subjects: 26
Study 10544630 — intervention group
Group type: EXPERIMENTAL
Intervention: Full protective gear
Number of subjects: 60
Study 10544630 — intervention group
Group type: COMPARATOR
Intervention: Fatigues (Control)
Number of subjects: 60
Study 8895048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor replacing part of sulphonylurea in Group 1 (n = 8)
Number of subjects: 36
Study 8895048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor replacing part of insulin in Group 2 (n = 10)
Number of subjects: 36
Study 8895048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor added to insulin without changing insulin dose in Group 3 (n = 9)
Number of subjects: 36
Study 8895048 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-glucosidase inhibitor added to sulphonylurea in Group 4 (n = 9)
Number of subjects: 36
Study 1900686 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced Hypertension Chemotherapy (IHC) using angiotensin II human (TY-10721) with adriamycin (33 mg/m2, day 3), 5-fluorouracil (330 mg/m2/day through day 1 to 3, 8 to 10), and mitomycin C (5 mg/m2, day 8), repeated every 4 weeks.
Number of subjects: 62
Study 1900686 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-IHC) receiving the same drugs via ordinary i.v. injection.
Number of subjects: 62
Study 6807126 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 0
Study 6807126 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 0
Study 30979939 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of calprotectin, von Willebrand factor, angiotensinogen, IL8, IL15, IP10, TNFα
Number of subjects: 1778
Study 30979939 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased levels of leptin, heparin cofactor 2, and serum paraoxonase
Number of subjects: 1778
Study 30979939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase responses, cellular responses to lipopolysaccharide, neutrophil responses to bacteria, and endothelial responses
Number of subjects: 1778
Study 30979939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-like profile
Number of subjects: 1778
Study 27894601 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with ramucirumab (10 mg/kg every 2 weeks and 150 mg daily)
Number of subjects: 462
Study 27894601 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with ramucirumab
Number of subjects: 462
Study 27894601 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib with placebo
Number of subjects: 462
Study 26768436 — intervention group
Group type: EXPERIMENTAL
Intervention: gabapentin + dexamethasone + 5HT3 receptor antagonist
Number of subjects: 413
Study 26768436 — intervention group
Group type: COMPARATOR
Intervention: placebo + dexamethasone + 5HT3 receptor antagonist
Number of subjects: 413
Study 25051811 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical counseling training
Number of subjects: 56
Study 25051811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured training)
Number of subjects: 56
Study 21508859 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg
Number of subjects: 20
Study 21508859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19153374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin supplementation (pyridoxine, cobalamin, and folic acid)
Number of subjects: 300
Study 19153374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin supplementation (pyridoxine, cobalamin, and folic acid)
Number of subjects: 300
Study 17214789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, individual educational training on breast cancer screening
Number of subjects: 79
Study 17214789 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic education on breast cancer screening
Number of subjects: 79
Study 15545586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular tonsillectomy using low-temperature plasma excision (n = 27)
Number of subjects: 55
Study 15545586 — intervention group
Group type: COMPARATOR
Intervention: Total tonsillectomy using conventional electrosurgery (n = 28)
Number of subjects: 55
Study 16200718 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + micronized progesterone (100 mg/d) in group 1 (G1)
Number of subjects: 60
Study 16200718 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (1.5 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 2 (G2)
Number of subjects: 60
Study 16200718 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (0.75 mg of 17 beta‐estradiol/d) + micronized progesterone (100 mg/d) in group 3 (G3)
Number of subjects: 60
Study 16200718 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel (0.75 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 4 (G4)
Number of subjects: 60
Study 9029746 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered immediately after pholcodine (25 g)
Number of subjects: 4
Study 9029746 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 2 hours after pholcodine (25 g)
Number of subjects: 4
Study 9029746 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 5 hours after pholcodine (25 g)
Number of subjects: 4
Study 9029746 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of activated charcoal (10 g every 12 h for 84 h)
Number of subjects: 4
Study 9029746 — intervention group
Group type: COMPARATOR
Intervention: Pholcodine administered on an empty stomach with water only (100 mg)
Number of subjects: 4
Study 8200955 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (15.8 mmol/day) for 4 weeks
Number of subjects: 9
Study 8200955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3310941 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of administered norfloxacin twice daily for three days
Number of subjects: 209
Study 3310941 — intervention group
Group type: COMPARATOR
Intervention: 800 mg of sulfamethoxazole and 160 mg of trimethoprim administered twice daily for ten days
Number of subjects: 209
Study 30614004 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (75 mg of DHA/kg/d for 14 days)
Number of subjects: 110
Study 30614004 — intervention group
Group type: COMPARATOR
Intervention: Control (high oleic sunflower oil for 14 days)
Number of subjects: 110
Study 29903984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 8
Study 29903984 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MD)
Number of subjects: 8
Study 27537926 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 28
Study 27537926 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg lidocaine
Number of subjects: 28
Study 27537926 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg lidocaine
Number of subjects: 28
Study 27537926 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lidocaine
Number of subjects: 28
Study 27537926 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lidocaine
Number of subjects: 28
Study 27537926 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature discrimination test
Number of subjects: 28
Study 27537926 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study 25364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving for an ill or dependent family member
Number of subjects: 48
Study 25364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandparenting and parenting an adult child
Number of subjects: 48
Study 25364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Death of a loved one
Number of subjects: 48
Study 25364998 — intervention group
Group type: EXPERIMENTAL
Intervention: Redemption and mutual fulfillment as caregivers, reconciliations with adult children, and legacy‐building as grandparents
Number of subjects: 48
Study 23210199 — intervention group
Group type: COMPARATOR
Intervention: Modified corticotomy-facilitated orthodontic tooth movement alone (Group I)
Number of subjects: 20
Study 23210199 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified corticotomy-facilitated orthodontic tooth movement combined with bone grafting (Group II)
Number of subjects: 20
Study 20520288 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (40 mg/d)
Number of subjects: 9
Study 20520288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/d)
Number of subjects: 9
Study 18467316 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy (CHRT) with 60 Gy, infusional 5-FU (300 mg/m²/day for 6 weeks), and intermittent cisplatin (20 mg/m²/day during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m² weekly for 3/4 weeks)
Number of subjects: 119
Study 18467316 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m² weekly for 7 weeks) followed by maintenance gemcitabine (1000 mg/m² weekly for 3/4 weeks)
Number of subjects: 119
Study 18467316 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy (CHRT)
Number of subjects: 119
Study 18467316 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 119
Study 16321132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-table standing for 30 minutes, three times per week for 12 weeks
Number of subjects: 20
Study 12865191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (oestradiol valerate and medroxyprogesterone acetate)
Number of subjects: 885
Study 12865191 — intervention group
Group type: COMPARATOR
Intervention: Dermal HRT (17 beta‐oestradiol gel with oral progestogen)
Number of subjects: 885
Study 10903586 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with compression
Number of subjects: 30
Study 10903586 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy program (Control)
Number of subjects: 30
Study 8880021 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid
Number of subjects: 18
Study 8880021 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg acetylsalicylic acid
Number of subjects: 18
Study 8880021 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 18
Study 1813707 — intervention group
Group type: EXPERIMENTAL
Intervention: Management with vasoactive substances and surgical removal of the focus
Number of subjects: 95
Study 1813707 — intervention group
Group type: COMPARATOR
Intervention: Postoperative management
Number of subjects: 95
Study 6403151 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support offered to children and families during the trial
Number of subjects: 0
Study 6403151 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the clinical trial
Number of subjects: 0
Study 6403151 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection criteria for participants
Number of subjects: 0
Study 31474281 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention (brief in-class writing assignment about personal values)
Number of subjects: 820
Study 31474281 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 820
Study 29913085 — intervention group
Group type: EXPERIMENTAL
Intervention: TimeStamper software for coding prelinguistic vocalizations in real time
Number of subjects: 0
Study 27358299 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous and intermittent feeding regimen
Number of subjects: 26
Study 27358299 — intervention group
Group type: COMPARATOR
Intervention: Intermittent feeding regimen
Number of subjects: 26
Study 24459677 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantic molecular resonance scalpel (QMRS)
Number of subjects: 85
Study 24459677 — intervention group
Group type: COMPARATOR
Intervention: Traditional scalpel (TS)
Number of subjects: 85
Study 22248672 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 16 weeks
Number of subjects: 32
Study 22248672 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for 16 weeks
Number of subjects: 32
Study 22248672 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 32
Study 20010070 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily)
Number of subjects: 256
Study 20010070 — intervention group
Group type: COMPARATOR
Intervention: DRV/r with two nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 256
Study 17346436 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBL sublingual treatment
Number of subjects: 41
Study 17346436 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study 16402646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal corticosteroids
Number of subjects: 11
Study 16402646 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 11
Study 14582440 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine and perindopril (combined treatment)
Number of subjects: 0
Study 14582440 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (6-month therapy)
Number of subjects: 0
Study 14582440 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (6-month therapy)
Number of subjects: 0
Study 10380088 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2,000 mcg
Number of subjects: 20
Study 10380088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 mcg
Number of subjects: 20
Study 10380088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8678627 — intervention group
Group type: EXPERIMENTAL
Intervention: Shed mediastinal RBCs
Number of subjects: 26
Study 8678627 — intervention group
Group type: COMPARATOR
Intervention: Circulating RBCs
Number of subjects: 26